Reviva Pharmaceutcls Hldgs Inc Stock Price, News & Analysis

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced that its Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will present a poster at the 78th Annual Scientific Convention of the Society of Biological Psychiatry from April 27-29, 2023, in San Diego, CA. The presentation, titled "Brilaroxazine (RP5063), a novel serotonin-dopamine stabilizer, displays antipsychotic efficacy in rodents," will take place on April 29, 2023, from 5:00-7:00 PM PT.

Brilaroxazine is a drug candidate showing significant clinical promise for treating schizophrenia and related disorders. In Phase 2 studies, it met primary endpoints, demonstrating efficacy with no adverse effects on weight or metabolic parameters. Additionally, it has potential applications in pulmonary diseases like PAH and IPF, having received Orphan Drug Designation from the FDA. Reviva aims to pursue further development of brilaroxazine for various neuropsychiatric conditions.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) will feature on The RedChip Money Report® on Bloomberg TV on April 22, 2023, at 7 p.m. ET. The interview includes insights from CEO Laxminarayan Bhat regarding the Company’s Phase 3 trial for schizophrenia and promising safety and efficacy results from the Phase 2 study. Reviva’s focus is on developing next-generation therapeutics to address unmet medical needs, with ongoing research on drug candidates like brilaroxazine (RP5063) and RP1208. Reviva holds composition of matter patents for both candidates in the U.S. and Europe. The RedChip Money Report® aims to provide investors with valuable information on small-cap investing and features various financial insights.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) reported financial results for the year ended December 31, 2022, highlighting significant progress towards brilaroxazine's NDA submission for treating schizophrenia. The pivotal Phase 3 RECOVER trial has enrolled over 50% of its 400 patients, with topline data expected mid-2023. The company reported a net loss of approximately $24.3 million, or $1.25 per share, compared to a loss of $8.5 million, or $0.58 per share in 2021. Cash and equivalents stood at $18.5 million as of December 31, 2022, sufficient to support operations through Q3 2023.

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced that its CEO Laxminarayan Bhat will present at the 35th Annual Roth Conference from March 12-14, 2023, in Dana Point, California. The presentation will take place on March 13 at 3:00 p.m. PT. Reviva focuses on developing therapies for unmet medical needs, particularly in central nervous system, cardiovascular, metabolic, and inflammatory diseases. Their pipeline includes drug candidates brilaroxazine (RP5063) and RP1208. For more details, visit the webcast link.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a clinical-stage pharmaceutical company, will have its Founder and CEO, Laxminarayan Bhat, present at the BIO CEO and Investor Conference from February 6–9, 2023 in New York. The presentation is scheduled for February 6 at 11:30 p.m. EST. Reviva focuses on developing therapies for unmet medical needs in central nervous system, cardiovascular, metabolic, and inflammatory diseases. Their pipeline includes drug candidates RP5063 (brilaroxazine) and RP1208, both with composition of matter patents in multiple regions.

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced progress in its Phase 3 RECOVER trial for brilaroxazine, targeting schizophrenia, with top-line data expected in mid-2023. Approximately 40% of patients have been treated with no serious adverse events reported. The company secured $8.5 million in funding to support this trial. Additionally, they completed a drug-drug interaction study showing brilaroxazine's favorable safety profile. Reviva aims to explore other indications, representing a combined market opportunity exceeding $70 billion. Upcoming milestones include potential NDA submission in 2025.

Reviva Pharmaceuticals Holdings announces positive results from a clinical drug-drug interaction study for brilaroxazine, a serotonin/dopamine modulator, essential for schizophrenia treatment. The study reinforces brilaroxazine's safety profile, showing no significant adverse interactions with CYP3A4 enzyme inhibitors. Topline data from the pivotal Phase 3 RECOVER trial is expected mid-2023, involving 400 patients over a 28-day regimen. The FDA may consider a 'Superior Safety' label for brilaroxazine based on positive Phase 3 results.

Reviva Pharmaceuticals (NASDAQ: RVPH) reported significant progress in its pivotal Phase 3 RECOVER trial for brilaroxazine, with over 30% patient enrollment across U.S. sites and expansion into Europe and India expected by year-end. Financially, the company recorded a net loss of $3.5 million for Q3 2022, compared to $2.3 million in Q3 2021, and had $23.2 million in cash as of September 30, 2022. Reviva anticipates topline data for the trial in mid-2023 and is exploring partnerships for further development in various neuropsychiatric and pulmonary indications.

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced significant progress in its Phase 3 RECOVER study for brilaroxazine, a treatment for schizophrenia, with over 30% enrollment in the U.S. and ongoing sites in Europe. The company expects to begin enrollment in Asia by November 2022. No major safety concerns have been reported in the trial, which is designed to assess brilaroxazine's efficacy across approximately 400 patients. Topline data is anticipated in mid-2023, reinforcing the potential of brilaroxazine to address the needs of approximately 24 million individuals living with schizophrenia globally.